PATIENT MEDICAL RECORD - DEMO FILE

=====================================================
Hospital Name: City Medical Center
Date: February 21, 2026
Record ID: HAL-DEMO-001
=====================================================

PATIENT INFORMATION:
Name: John Smith (Demo Patient)
Age: 58
Gender: Male
Medical Record Number: 123456
Admission Date: February 15, 2026

CHIEF COMPLAINT:
Persistent cough, shortness of breath, and chest pain

HISTORY OF PRESENT ILLNESS:
Patient is a 58-year-old male with a 40 pack-year smoking history
presenting with persistent cough lasting 3 weeks, progressive shortness
of breath, and occasional chest pain. Patient reports weight loss of
5 kg over the past month.

PAST MEDICAL HISTORY:
- Chronic Obstructive Pulmonary Disease (COPD)
- Hypertension (controlled with medication)
- Type 2 Diabetes Mellitus
- Hyperlipidemia

PHYSICAL EXAMINATION:
- Blood Pressure: 145/92 mmHg
- Heart Rate: 88 bpm
- Respiratory Rate: 22 breaths/min
- Temperature: 37.2°C
- Oxygen Saturation: 89% (room air)
- Lung auscultation: Decreased breath sounds bilaterally

DIAGNOSTIC IMAGING:
CT Chest with Contrast (February 18, 2026):
- 5.8 cm mass in left upper lobe
- Mediastinal lymphadenopathy
- Pleural effusion on left side (approximately 600 mL)
- No evidence of distant metastases

PET Scan (February 20, 2026):
- Hypermetabolic activity in left upper lobe mass
- Regional lymph node involvement
- SUV max: 8.2 (suggestive of malignancy)

LABORATORY RESULTS:
- CBC: Mild anemia, WBC normal
- Comprehensive Metabolic Panel: Within normal limits
- Tumor Markers: CEA 12.5 ng/mL (elevated)

PATHOLOGY:
Lung Biopsy (Transbronchial) - February 19, 2026:
Diagnosis: Adenocarcinoma of lung, non-small cell type (NSCLC)
Grade: Moderately differentiated
Mitotic count: 7 per 10 high power fields
Ki-67 index: 35%

IMMUNOHISTOCHEMISTRY:
- TTF-1: Positive
- CK7: Positive
- CK20: Negative
- EGFR Mutation: Positive (activating mutation)
- ALK Status: Negative

TUMOR STAGING (TNM Classification):
- T: 3 (tumor >3cm, invasion into chest wall)
- N: 2 (ipsilateral mediastinal lymphadenopathy)
- M: 0 (no distant metastases)
- Overall Stage: IIIA (locally advanced)

TREATMENT PLAN:
Phase 1 - Chemotherapy:
- Regimen: Cisplatin 75 mg/m² + Pemetrexed 500 mg/m²
- Schedule: Every 3 weeks for 4 cycles
- Start Date: February 28, 2026
- Expected completion: June 2026

Phase 2 - Radiation Therapy (if residual disease):
- Dose: 60 Gy in 30 fractions
- Planned target: Left upper lobe and mediastinal lymph nodes
- Expected dates: July-August 2026

Phase 3 - Maintenance Therapy:
- Pemetrexed continuation therapy for up to 2 additional years
- Close monitoring with CT imaging every 3 months

PROGNOSIS:
5-year overall survival with multi-modality treatment: 20-30%
Patient counseled on treatment risks and benefits
Alternative treatment options discussed

MEDICATIONS:
- Cisplatin (chemotherapy)
- Pemetrexed (chemotherapy)
- Ondansetron (anti-nausea)
- Dexamethasone (corticosteroid)
- Supportive care medications

PATIENT EDUCATION:
- Smoking cessation counseling provided
- Nutrition counseling recommended
- Fatigue management strategies discussed
- Support group referrals provided
- Advance directive discussion completed

FOLLOW-UP CARE:
- Oncology clinic: Every 3 weeks during chemotherapy
- CT imaging: Post-treatment (July 2026)
- Pulmonology: As needed for respiratory symptoms
- Primary Care: Monthly monitoring

KEYWORDS EXTRACTED FOR SEARCH:
cancer, lung, chemotherapy, cisplatin, pemetrexed, nsclc, adenocarcinoma,
malignant, tumor, diagnosis, treatment, prognosis, oncology, biopsy,
radiotherapy, imaging, clinical, patient, medical, research, healthcare,
therapy, medication, hospital, physician, respiratory, pulmonology,
disease, metastases, lymph, nodes, staging, ttf, ck7, egfr, mutation,
ki67, immunohistochemistry